AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enroll...AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enrolled to investigate the expression of mi R-20 a and let-7a using quantitative real-time PCR. The expression of mi R-20 a and let-7a was compared between ESCC patients and healthy subjects. The plasma levels of mi R-20 a and let-7a in relation to patient clinicopathologic parameters, the receiver operating characteristic(ROC) curve, and the sensitivity and specificity of mi R-20 a and let-7a in ESCC diagnosis were analyzed.RESULTS: Plasma levels of mi R-20 a were significantly higher in ESCC patients than in healthy controls, and plasma levels of let-7 were lower in ESCC patients than in healthy controls(both P < 0.05). The area under the ROC curve of mi R-20 a was 0.767(95%CI: 0.677-0.857; P < 0.001), when the cut-off value was set at 4.77, the sensitivity and specificity were 64.3% and 75.0%, respectively. The area under the ROC curve of let-7a was 0.829(95%CI: 0.754-0.904; P < 0.001), when the cut-off value was set at 6.22, the sensitivity and specificity were 74.3% and 85.0%, respectively. Thus, the sensitivity and specificity of let-7a were higher than those of mi R-20 a. The median relative plasma expression of let-7a in clinical stage Ⅲ/Ⅳ(0.24) was lower than that in stage Ⅰ/Ⅱ(0.42), while the expression of mi R-20 a according to stage was not statistically different. The expressions of mi R-20 a and let-7a were not related to gender, age, tumor diameter, tumor grade, or pathologic stage.CONCLUSION: Plasma mi R-20 a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.展开更多
目的探讨血清表面活性蛋白D(surfactant protein D,SP-D)、黏蛋白1(mucin 1,MUC1)、锌指蛋白A20(zinc finger protein A20,A20)水平对输血相关性急性肺损伤(transfusion-related acute lung injury,TRALI)患者临床预后的预测价值,以期...目的探讨血清表面活性蛋白D(surfactant protein D,SP-D)、黏蛋白1(mucin 1,MUC1)、锌指蛋白A20(zinc finger protein A20,A20)水平对输血相关性急性肺损伤(transfusion-related acute lung injury,TRALI)患者临床预后的预测价值,以期临床个体化干预提供参考。方法选取2020年3月—2025年3月河北省胸科医院收治的TRALI患者249例为研究对象,根据输血后30 d内预后情况,分别纳入预后良好组(178例)、预后不良组(71例)。比较2组一般临床资料及血清SP-D、MUC1、A20水平,Logistic回归分析血清SP-D、MUC1、A20水平对TRALI患者预后不良的影响因素,受试者工作特征(receiver operating characteristic,ROC)曲线分析血清SP-D、MUC1、A20水平单独及联合检测对预后不良的预测效能,并采用一致性分析进行外部验证。结果2组输血次数、发血至输血时间、过敏史、急性生理与慢性健康评分系统Ⅱ(acute physiology and chronic health evaluationⅡ,APACHEⅡ)评分比较,差异有统计学意义(P<0.05);预后不良组血清SP-D、MUC1、A20水平分别为(89.54±21.36)g/L、(22.97±5.14)kU/L、(14.53±1.96)mg/L,明显高于预后良好组的(78.61±18.05)g/L、(16.28±4.32)kU/L、(12.67±1.84)mg/L,差异有统计学意义(P<0.05);Logistic回归分析显示,输血次数、发血至输血时间、过敏史均是TRALI患者预后不良的影响因素(P<0.05),APACHEⅡ评分及血清SP-D、MUC1、A20均与TRALI患者预后不良显著相关(P<0.05);ROC分析显示,血清SP-D、MUC1、A20联合预测预后不良的曲线下面积(area under the curve,AUC)为0.904(95%CI:0.860~0.938),优于各指标单独预测价值(Z=2.507、3.016、3.042,均P<0.05),且外部验证显示,联合预测预后不良与临床实际的符合率为95.00%,Kappa值为0.870(95%CI:0.617~0.982)差异有统计学意义(P<0.05)。结论血清SP-D、MUC1、A20均是TRALI患者预后不良的独立影响因素,联合检测对预后不良具有较高预测价值,可作为TRALI患者预后的潜在预测因子,并可指导临床工作。展开更多
基金Supported by Medical Scientific Research Foundation of Health Department of Henan Province of China,No.201403077
文摘AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enrolled to investigate the expression of mi R-20 a and let-7a using quantitative real-time PCR. The expression of mi R-20 a and let-7a was compared between ESCC patients and healthy subjects. The plasma levels of mi R-20 a and let-7a in relation to patient clinicopathologic parameters, the receiver operating characteristic(ROC) curve, and the sensitivity and specificity of mi R-20 a and let-7a in ESCC diagnosis were analyzed.RESULTS: Plasma levels of mi R-20 a were significantly higher in ESCC patients than in healthy controls, and plasma levels of let-7 were lower in ESCC patients than in healthy controls(both P < 0.05). The area under the ROC curve of mi R-20 a was 0.767(95%CI: 0.677-0.857; P < 0.001), when the cut-off value was set at 4.77, the sensitivity and specificity were 64.3% and 75.0%, respectively. The area under the ROC curve of let-7a was 0.829(95%CI: 0.754-0.904; P < 0.001), when the cut-off value was set at 6.22, the sensitivity and specificity were 74.3% and 85.0%, respectively. Thus, the sensitivity and specificity of let-7a were higher than those of mi R-20 a. The median relative plasma expression of let-7a in clinical stage Ⅲ/Ⅳ(0.24) was lower than that in stage Ⅰ/Ⅱ(0.42), while the expression of mi R-20 a according to stage was not statistically different. The expressions of mi R-20 a and let-7a were not related to gender, age, tumor diameter, tumor grade, or pathologic stage.CONCLUSION: Plasma mi R-20 a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
文摘目的探讨血清表面活性蛋白D(surfactant protein D,SP-D)、黏蛋白1(mucin 1,MUC1)、锌指蛋白A20(zinc finger protein A20,A20)水平对输血相关性急性肺损伤(transfusion-related acute lung injury,TRALI)患者临床预后的预测价值,以期临床个体化干预提供参考。方法选取2020年3月—2025年3月河北省胸科医院收治的TRALI患者249例为研究对象,根据输血后30 d内预后情况,分别纳入预后良好组(178例)、预后不良组(71例)。比较2组一般临床资料及血清SP-D、MUC1、A20水平,Logistic回归分析血清SP-D、MUC1、A20水平对TRALI患者预后不良的影响因素,受试者工作特征(receiver operating characteristic,ROC)曲线分析血清SP-D、MUC1、A20水平单独及联合检测对预后不良的预测效能,并采用一致性分析进行外部验证。结果2组输血次数、发血至输血时间、过敏史、急性生理与慢性健康评分系统Ⅱ(acute physiology and chronic health evaluationⅡ,APACHEⅡ)评分比较,差异有统计学意义(P<0.05);预后不良组血清SP-D、MUC1、A20水平分别为(89.54±21.36)g/L、(22.97±5.14)kU/L、(14.53±1.96)mg/L,明显高于预后良好组的(78.61±18.05)g/L、(16.28±4.32)kU/L、(12.67±1.84)mg/L,差异有统计学意义(P<0.05);Logistic回归分析显示,输血次数、发血至输血时间、过敏史均是TRALI患者预后不良的影响因素(P<0.05),APACHEⅡ评分及血清SP-D、MUC1、A20均与TRALI患者预后不良显著相关(P<0.05);ROC分析显示,血清SP-D、MUC1、A20联合预测预后不良的曲线下面积(area under the curve,AUC)为0.904(95%CI:0.860~0.938),优于各指标单独预测价值(Z=2.507、3.016、3.042,均P<0.05),且外部验证显示,联合预测预后不良与临床实际的符合率为95.00%,Kappa值为0.870(95%CI:0.617~0.982)差异有统计学意义(P<0.05)。结论血清SP-D、MUC1、A20均是TRALI患者预后不良的独立影响因素,联合检测对预后不良具有较高预测价值,可作为TRALI患者预后的潜在预测因子,并可指导临床工作。
